REBEC

Go to main content [1]
Go to main menu [2]
Enable hight contrast [3]

-

-

-

-

-

Public trial

The immediate effect of Intermittent Hypoxia on Parkinson's Disease and its effects on gait, sleep quality, and blood biomarkers

Date of registration: 05/07/2024 ^(mm/dd/yyyy)
Last approval date : 05/07/2024 ^(mm/dd/yyyy)
Last revision: 1

Study type:

Interventional

Laser effects in women with vocal disorders

Date of registration: 05/07/2024 ^(mm/dd/yyyy)
Last approval date : 05/07/2024 ^(mm/dd/yyyy)
Last revision: 1

Study type:

Interventional

Effects of Spinal Cord Electrostimulation on Chronic Pain

Date of registration: 05/06/2024 ^(mm/dd/yyyy)
Last approval date : 05/06/2024 ^(mm/dd/yyyy)
Last revision: 1

Study type:

Interventional

Clinical study of children health

Date of registration: 05/02/2024 ^(mm/dd/yyyy)
Last approval date : 05/02/2024 ^(mm/dd/yyyy)
Last revision: 1

Study type:

Interventional

Effect of Floral Therapy on Anxiety in caregivers of elderly individuals at home

Date of registration: 05/02/2024 ^(mm/dd/yyyy)
Last approval date : 05/02/2024 ^(mm/dd/yyyy)
Last revision: 1

Study type:

Interventional

Benefits of Gestational Diabetes Education for Pregnant Women

Date of registration: 05/02/2024 ^(mm/dd/yyyy)
Last approval date : 05/02/2024 ^(mm/dd/yyyy)
Last revision: 1

Study type:

Observational

Influence of ozone on color change and pain during at-home dental bleaching: a clinical trial

Date of registration: 05/02/2024 ^(mm/dd/yyyy)
Last approval date : 05/02/2024 ^(mm/dd/yyyy)
Last revision: 1

Study type:

Interventional

Influence of different products on the effectiveness and duration of treatment of sensitive teeth and patients' well-being

Date of registration: 05/02/2024 ^(mm/dd/yyyy)
Last approval date : 05/02/2024 ^(mm/dd/yyyy)
Last revision: 1

Study type:

Interventional

The effect of Manual Treatment in patients with type 2 Diabetes

Date of registration: 04/30/2024 ^(mm/dd/yyyy)
Last approval date : 04/30/2024 ^(mm/dd/yyyy)
Last revision: 1

Study type:

Interventional

Effects of Cannabis Oil on respiratory and cardiovascular function in healthy individuals: a randomized clinical trial study

Date of registration: 04/30/2024 ^(mm/dd/yyyy)
Last approval date : 04/30/2024 ^(mm/dd/yyyy)
Last revision: 1

Study type:

Interventional

Effect of Dry Needling on the psychoacoustic characteristics of Somatosensory Tinnitus

Date of registration: 04/30/2024 ^(mm/dd/yyyy)
Last approval date : 04/30/2024 ^(mm/dd/yyyy)
Last revision: 1

Study type:

Interventional

Assessment of a cryotherapy crpotocol on the occurrence of postoperative endodontic pain in molars with irreversible pulpitis: a randomized clinical trial

Date of registration: 04/29/2024 ^(mm/dd/yyyy)
Last approval date : 04/29/2024 ^(mm/dd/yyyy)
Last revision: 1

Study type:

Interventional

Impact of abreviation of preoperative fasting on cost-effectiveness in surgical patients

Date of registration: 04/29/2024 ^(mm/dd/yyyy)
Last approval date : 04/29/2024 ^(mm/dd/yyyy)
Last revision: 1

Study type:

Observational

Long-term evaluation of teeth supporting a removable partial denture - influence of plaque disclosing agent on dental cleaning

Date of registration: 04/29/2024 ^(mm/dd/yyyy)
Last approval date : 04/29/2024 ^(mm/dd/yyyy)
Last revision: 1

Study type:

Interventional

Treatment of ligneous conjunctivitis with platelet-rich plasma

Date of registration: 04/29/2024 ^(mm/dd/yyyy)
Last approval date : 04/29/2024 ^(mm/dd/yyyy)
Last revision: 1

Study type:

Interventional

Effect of Two Procedures for Dressing the Roof of the Mouth Evaluating Pain, Quality of Life and Healing in People Who Underwent Gum Grafting

Date of registration: 04/28/2024 ^(mm/dd/yyyy)
Last approval date : 04/28/2024 ^(mm/dd/yyyy)
Last revision: 1

Study type:

Interventional

Impact of Cerebral Oximetry Monitoring on Postoperative Hemodynamic Outcomes in Patients Undergoing Cardiac Surgery with Cardiopulmonary Bypass

Date of registration: 04/27/2024 ^(mm/dd/yyyy)
Last approval date : 04/27/2024 ^(mm/dd/yyyy)
Last revision: 1

Study type:

Observational

Effect of online Psychotherapy on the quality of life of old people

Date of registration: 04/26/2024 ^(mm/dd/yyyy)
Last approval date : 04/26/2024 ^(mm/dd/yyyy)
Last revision: 1

Study type:

Interventional

Effects of early treatment of anterior open bite with orthodontic aligners and removable palatal crib

Date of registration: 04/26/2024 ^(mm/dd/yyyy)
Last approval date : 04/26/2024 ^(mm/dd/yyyy)
Last revision: 1

Study type:

Interventional

Use of technologies for distraction of children during dental care

Date of registration: 04/26/2024 ^(mm/dd/yyyy)
Last approval date : 04/26/2024 ^(mm/dd/yyyy)
Last revision: 1

Study type:

Interventional

Username/Password

News

04/23/2026

Why these treatments for one of the deadliest cancers are stirring such hope

04/22/2026 | Carolyn Y. Johnson/Christopher Rowland | Washington Post

https://www.washingtonpost.com/health/2026/04/22/cancer-pancreatic-treatment-clinical-trial/

Pancreatic cancer has stymied treatment advances for decades. Data from new clinical trials shows promise.

Experimental therapies with radically different approaches are stirring a wave of optimism that survival rates could substantially improve for pancreatic cancer, one of the most stubbornly lethal forms of the disease.

Giving doctors and patients more options to standard chemotherapy would “increase shots on goal” and perhaps even make the dreaded diagnosis manageable over a number of years, according to experts.

The furthest along and generating the most excitement is a pill developed by Revolution Medicines, which inhibits a protein that signals cancer cells to multiply and drives tumor formation and growth. Phase 3 clinical trial results announced this month showed patients treated with the new drug, called daraxonrasib, had median survival of 13.2 months compared to 6.7 months for people receiving chemotherapy.

The Food and Drug Administration has put the drug on its speediest track for approval, meaning it could be approved this year. Ben Sasse, the former U.S. senator from Nebraska, is taking the drug to treat his pancreatic cancer and gave an interview to the New York Times about his experience, elevating public interest.

“We have moved from famine to feast in this disease,” said Shubham Pant, an oncologist who specializes in treating gastrointestinal cancers at the University of Texas MD Anderson Cancer Center. He spoke in San Diego on Tuesday at an American Association for Cancer Research conference session entitled, “Turning the tide in the fight against pancreatic…

04/23/2026

CHEO Research Institute strengthens pediatric clinical trials in Canada

04/23/2026 | CHEO Research Institute

https://www.cheo.on.ca/en/news/cheo-research-institute-strengthens-pediatric-clinical-trials-in-canada.aspx

The CHEO Research Institute has launched its new Clinical Trial Access Core and Clinical Investigation Unit (CIU) — a significant investment designed to expand pediatric clinical trial capacity in the region and strengthen Canada’s clinical trials ecosystem.

Located within the CHEO Research Institute, one of Canada’s top 40 research hospitals, the new Clinical Trial Access Core brings together the infrastructure, expertise and operational support needed to lead and host more pediatric clinical trials in the nation's capital.

Clinical trials are an essential part of pediatric care, particularly in rare and complex conditions where approved treatments may be limited or unavailable. By strengthening its ability to conduct high-quality pediatric trials, the CHEO Research Institute is enabling greater access to innovative, and potentially life-sustaining therapies closer to home.

“This investment strengthens Canada’s clinical trials infrastructure, supports government priorities to grow a competitive research ecosystem, and most importantly, ensures children and families have access to innovative care where, and when, they need it most,” said Dr. Jason Berman, CEO and Scientific Director of the CHEO Research Institute, and Vice-President of Research, CHEO.

The launch of the Clinical Trial Access Core supports national efforts to strengthen Canada’s clinical trials capacity, enhance research competitiveness, and attract investment in life sciences and health innovation. By expanding pediatric trial infrastructure and operational readiness, the CHEO RI is helping Canada remain a destination for high-quality…

04/23/2026

The Rise — And Stall — Of Retail Pharmacy Clinical Trials

04/23/2026 | Dan Schell | Clinical Leader

https://www.clinicalleader.com/doc/the-rise-and-stall-of-retail-pharmacy-clinical-trials-0001

I’m warning you, what I’m about to say is a rumor.
You know, industry scuttlebutt.
Or as my daughter would say — the tea.

But I don’t think so.

See, more than one person (all of whom are smarter and more “connected” than me) has told me that Walgreens is getting out of the clinical trials game. Wait, I take that back, let me rephrase it … they are reassessing their commitment to pursuing their clinical trials strategy. I swear I’m not using AI for this stuff (maybe I should be!).

No matter how you phrase or spin it, I’m predicting something big is likely happening within the Walgreens Boots Alliance clinical trials business unit. Do I have proof? No. The company has not released any press release about this shift. When I did contact a representative from the company, they replied with the following:

“… please note that Walgreens/Sycamore will not be granting any formal interviews or furnish formal communications on the status of the business at this time.”

In case you don’t know, on August 28, 2025, Walgreens was acquired by Sycamore Partners, a mid-to-large private equity firm that took the retailer private. Fast forward nearly six months, and everything still seemed to be clicking with five Walgreens employees speaking in four different sessions at SCOPE about topics such patient engagement, RWE, and how retail pharmacies can improve access to clinical trials.

So, what changed since then?
I have no idea.

If I had to guess, considering a PE firm is now involved, I’d say it was a financial decision. But honestly, none of that matters,…

04/22/2026

After a heart attack, this treatment could prevent the worst : and researchers are optimistic

04/22/2026 | Futura

https://www.futura-sciences.com/en/after-a-heart-attack-this-treatment-could-prevent-the-worst-and-researchers-are-optimistic_30717/

A treatment that targets the immune system could help prevent repeat heart attacks in people who have recently had one, according to results from an early-stage clinical trial in Cambridge. Two years after joining the study, none of the participants who received the treatment had suffered another heart attack.

The treatment, called aldesleukin, reduces inflammation in major blood vessels by boosting the activity of regulatory T cells, part of the immune system. Aldesleukin is already used at much higher doses to treat certain kidney cancers.

Regulatory T cells, a distinct type of white blood cell, play a crucial role in protecting the immune system, and their discovery was recently recognized with the 2025 Nobel Prize in Physiology or Medicine.

“We are delighted that our early-phase trial, which tested the very mechanism considered a game changer by the Nobel Prize committee, has shown encouraging results that we hope to answer conclusively in larger trials.”
Dr. Joseph Cheriyan
A consultant clinical pharmacologist at Cambridge University Hospitals NHS Foundation Trust who led the trials

In the United Kingdom, someone is admitted to the hospital every five minutes because of a heart attack. While seven out of ten people will survive a heart attack, many are left with damaged hearts, which can raise the risk of future attacks.

People who have had a heart attack often show high levels of inflammation in major blood vessels, and that is a strong sign they may be at risk of another one.

At present, there is no approved treatment that specifically targets…

04/22/2026

Cristália promises to invest “whatever it takes” in polylaminin

04/22/2026 | César Ferro | Panorama Farmacêutico

https://panoramafarmaceutico.com.br/cristalia-promete-investir-o-que-for-necessario-na-polilaminina/

The laboratory has already allocated approximately R$ 150 million for the development of the molecule

Even after investing R$ 150 million in the development of polylaminin, Cristália continues to spare no effort in advancing the molecule through clinical trials. In an interview with Valor Econômico, the pharmaceutical company’s founder and chairman of the board, Ogari Pacheco, stated that the laboratory will contribute “whatever is necessary for the success of the innovation.”

The drug, which aims to regenerate spinal cord injuries, has sparked mixed reactions. On one hand, patients are seeking access to the experimental treatment through legal action. On the other, scientists outside the project are raising questions.

Led by scientist Tatiana Sampaio of the Federal University of Rio de Janeiro (UFRJ), the research has been supported by the company for eight years. The company’s funds financed the study and covered the cost of administering the drug to approximately 30 patients under compassionate use—when Anvisa authorizes its use in specific cases, even before formal approval.

Polylaminin patent is the first point of controversy
Cristália filed for a patent for the polylaminin manufacturing process at the national level in 2022. The following year, the application was also filed abroad, in markets such as the U.S., Europe, India, China, South Korea, and Latin America.

These applications are still under review, with no timeline for a decision. “Today, we are covered by this application, which provides us with protection both here and abroad,”…